Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 478Neoplasms, Plasma Cell 102Lymphoma 86Lymphoma, Non-Hodgkin 75Leukemia, Lymphocytic, Chronic, B-Cell 72Myelodysplastic Syndromes 71Recurrence 68Leukemia, Myeloid, Acute 68Leukemia 68Precursor Cell Lymphoblastic Leukemia-Lymphoma 67Hodgkin Disease 66Lymphoma, Mantle-Cell 53Lymphoma, Large B-Cell, Diffuse 53Lymphoma, Follicular 45Myeloproliferative Disorders 43Neoplasms 41Lymphoma, B-Cell, Marginal Zone 41Burkitt Lymphoma 41Primary Myelofibrosis 38Lymphoma, Large-Cell, Immunoblastic 36Lymphoma, T-Cell, Cutaneous 31Leukemia, Myelomonocytic, Chronic 31Sezary Syndrome 29Mycosis Fungoides 29Leukemia, Myeloid, Chronic-Phase 29Leukemia, Myeloid, Accelerated Phase 29Congenital Abnormalities 29Leukemia, Hairy Cell 27Blast Crisis 27Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 25

Interventions

ibrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Multi-centric Castleman's Disease × Plasma cell × Clear all
NCT02109224 2015-08-20

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

National Cancer Institute (NCI)

Phase 1 Terminated
72 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Multi-centric Castleman's Disease, Burkitt Lymphoma, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, HIV Infections, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡